Northwire Canada EditionSunday, July 12, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Regulatory Routine +

TelyRx Holdings Inc. to Commence Trading on the Toronto Stock Exchange Effective April 7, 2026

Delivering essential medication with no friction, no delays, and no barriers

By The Northwire Desk — AI Analysis Apr 07, 2026 · 07:01 TELY
Executive Summary
  • On April 7 2026, TelyRx Holdings Inc. commenced trading of its subordinate voting shares on the Toronto Stock Exchange under ticker TELY.
  • The listing follows completion of a go‑public transaction via a combination with Apolo V Acquisition Corp.
  • Management highlighted the company’s nationwide digital pharmacy platform covering 48 U.S. states and territories, offering more than 400 FDA‑approved medications through independent state‑licensed physicians and licensed retail pharmacies in Florida and Texas.
  • Service reach exceeds 97% of the U.S. population; the mission is to deliver essential medication “with no friction, no delays, and no barriers.”
  • Prior news (April 6 2026) announced final TSX approval for the uplisting and concurrent voluntary delisting from the TSX Venture Exchange.
Material Impact
  • The commencement of trading is the execution of a previously announced uplisting; it was expected after the April 6 approval.
  • No new financial guidance, material contract, or strategic partnership was disclosed alongside the listing.
  • Therefore the news represents a routine, positive development rather than a material game‑changer.
TELY · Price
Company Overview
  • TelyRx Holdings Inc. operates a vertically integrated, technology‑enabled digital pharmacy platform.
  • Platform serves over 97% of the U.S. population across 48 states and territories.
  • Offers more than 400 FDA‑approved medications via independent, state‑licensed physicians and licensed retail pharmacies in Florida and Texas.
  • Core mission: deliver essential medication with no friction, no delays, and no barriers.
Read the original news release →

More from

Jun 08, 2026 · 17:58

Digital Pharmacy Scales to 1M Prescriptions, But Growth Trajectory Faces Liquidity and Profitability Tests

Production / Operations Jun 08, 2026 · 08:01

Scaling a cash-pay digital pharmacy model, but liquidity and profitability remain unproven as the stock drifts lower post-IPO.

Production / Operations Apr 21, 2026 · 16:49

N/A

Earnings